Denali Therapeutics’ (NASDAQ:DNLI) lock-up period will expire on Wednesday, June 6th. Denali Therapeutics had issued 13,888,888 shares in its public offering on December 8th. The total size of the offering was $249,999,984 based on an initial share price of $18.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
A number of brokerages recently weighed in on DNLI. ValuEngine upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 17th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $23.25.
Shares of Denali Therapeutics opened at $20.80 on Tuesday, according to Marketbeat. Denali Therapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $25.79. The stock has a market cap of $1.78 billion and a P/E ratio of -3.53.
Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Friday, May 11th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.39). The business had revenue of $0.64 million for the quarter, compared to analysts’ expectations of $45.00 million. research analysts predict that Denali Therapeutics will post -0.74 EPS for the current year.
Institutional investors have recently modified their holdings of the business. Flagship Pioneering Inc. bought a new stake in Denali Therapeutics in the fourth quarter worth about $139,489,000. Artal Group S.A. bought a new stake in Denali Therapeutics in the fourth quarter worth about $7,820,000. Goldman Sachs Group Inc. bought a new stake in Denali Therapeutics in the fourth quarter worth about $2,189,000. Crestline Management LP bought a new stake in Denali Therapeutics in the fourth quarter worth about $321,782,000. Finally, Bridger Management LLC bought a new stake in Denali Therapeutics in the fourth quarter worth about $4,888,000. Hedge funds and other institutional investors own 63.79% of the company’s stock.
About Denali Therapeutics
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for the treatment of Parkinson's disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.